What is OWKIN?
Headquartered in New York, Owkin operates at the vanguard of the digital health revolution. By leveraging advanced artificial intelligence, the company empowers researchers to utilize data from diverse healthcare and research environments to train highly interpretable machine learning models. This capability is essential for navigating the complexities of clinical trials and patient stratification. Owkin's market position is defined by its ability to bridge the gap between raw medical data and clinical utility, effectively transforming how biopharmaceutical entities approach research and development. Through its unique federated learning approach, the company ensures data privacy while maximizing the predictive power of collaborative research networks.
How much funding has OWKIN raised?
OWKIN has raised a total of $225.1M across 4 funding rounds:
Angel/Seed
$2.1M
Other Financing Round
$25M
Series A
$18M
Private Equity
$180M
Angel/Seed (2016): $2.1M, investors not publicly disclosed
Other Financing Round (2020): $25M led by Bpifrance Large Venture
Series A (2020): $18M supported by Bpifrance and Mubadala GE Capital PJSC
Private Equity (2021): $180M featuring Sanofi
Key Investors in OWKIN
Sanofi
A global biopharmaceutical leader focused on scientific innovation across immunology, rare diseases, and oncology, providing strategic support for medical advancement.
Bpifrance
A French public investment bank that supports the growth of innovative companies through equity, credit, and strategic consulting services.
Mubadala GE Capital PJSC
A diversified investment firm focused on long-term value creation through strategic partnerships and capital deployment in high-growth sectors.
What's next for OWKIN?
Looking ahead, Owkin is poised to leverage its recent capital injection to deepen its strategic partnerships with global pharmaceutical leaders. The focus will likely shift toward expanding the deployment of its AI-driven platforms across broader therapeutic areas, including oncology and rare diseases. By enhancing its computational infrastructure, Owkin aims to reduce the time-to-market for life-saving therapies, thereby increasing the efficiency of the entire clinical development lifecycle. As the industry moves toward more data-centric research models, Owkin's ability to provide scalable, secure, and interpretable AI solutions will be a primary driver of its long-term competitive advantage and sustained growth in the global health-tech ecosystem.
See full OWKIN company page
